DelMar's Abstract "Phase I/II study of VAL-083 in patients with recurrent glioblastoma multiforme" at American Association of Cancer Research (AACR) Annual Meeting Apr 6, 2014
DelMar's Presentation Poster for VAL-083 in Glioblastoma at Society for Neuro-Oncology (SNO) Dec 4, 2013
DelMar's Presentation Poster "The unique mechanism of action of VAL-083 may provide a new treatment option for some chemo-resistant cancers" at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Oct 21, 2013
DelMar's Presentation Poster "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer" at American Association of Cancer Research (AACR) Annual Meeting Apr 1, 2013
DelMar's Presentation Poster "Phase I/II Study of VAL-083 in Patients with Recurrent Malignant Glioma or Progressive-Secondary Brain Tumor" at Society for Neuro-Oncology (SNO) Annual Meeting 2012 Nov 1, 2012
DelMar's Presentation Poster "Phase I/II Study of VAL-083 in Patients with Recurrent Malignant Glioma or Progressive-Secondary Brain Tumor" at Society for Neuro-Oncology (SNO) Annual Meeting 2012 Nov 1, 2012
DelMar's abstract "VAL-083, a novel N7 alkylating agent, surpasses temozolomide activity and inhibits cancer stem cells providing a new potential treatment option for glioblastoma multiforme" at Society for Neuro-Oncology (SNO) Annual Meeting 2012 Nov 1, 2012
DelMar's abstract "VAL083, a novel N7 alkylating agent, surpasses temozolomide activity and inhibits cancer stem cells providing a new potential treatment option for glioblastoma multiforme" at American Association of Cancer Research (AACR) Annual Meeting Apr 1, 2012
